

## Leiomyosarcoma of the breast - a case report\*

Memenin leiomyosarkomu - bir olgu sunumu\*

Nuray Can<sup>1</sup>, Şemsi Altaner<sup>2</sup>, Fulya Öz Puyan<sup>2</sup>, Zeynep Peğlivanoğlu<sup>2</sup>, A. Kemal Kutlu<sup>2</sup>

<sup>1</sup>Şanlıurfa Education and Research Hospital, Department of Pathology, Şanlıurfa

<sup>2</sup>Trakya University, Faculty of Medicine, Department of Pathology, Edirne

### Abstract

Primary leiomyosarcomas of the breast are extremely rare tumors. There were approximately thirty patients reported in the literature up to date. Herein, we report a 66-years old female patient who presented with an enlarging mass in her right breast which was diagnosed as primary leiomyosarcoma following previous mixed invasive ductal carcinoma and invasive lobular carcinoma in her left breast. Although primary leiomyosarcomas of the breast are very rare tumors, they should be kept in mind in the differential diagnosis of spindle cell breast tumors including metaplastic carcinoma in patients with prior breast cancer.

**Keywords:** Breast cancer; leiomyosarcoma

### Özet

Memenin primer leiomyosarkomları oldukça nadirdir. Literatürde bugüne kadar yaklaşık otuz hasta rapor edilmiştir. Bu olgu sunumunda, daha önce sol memesinde mikst invaziv duktal karsinom ve lobüler karsinom teşhisi olan, sağ memesinde büyüme gösteren kitle ile başvuran ve primer leiomyosarkom tanısı alan 66 yaşındaki kadın hasta bildirilmektedir. Memenin primer leiomyosarkomları çok nadir tümörler olmasına rağmen, meme kanseri öyküsü olan hastalarda ortaya çıkan içgisi hücreli meme tümörlerinin metaplastik karsinomu da içeren ayırıcı tanısında akılda tutulmalıdır.

**Anahtar kelimeler:** Meme kanseri; leiomyosarkom

### Introduction

Primary sarcomas of the breast are extremely rare, with less than 0.1% of all malignant tumors of the breast. Leiomyosarcomas belong to a less common subgroup (5% to 10%) of breast sarcomas (1). Leiomyosarcoma probably originates from blood vessels, the smooth muscle of the nipple-areolar complex or myofibroblasts (2). Herein, we report a case of primary leiomyosarcoma of the breast occurring 18-months after the diagnosis of mixed invasive ductal and lobular carcinoma of her other breast.

### Case

A 66-years old female patient with a mass in her left breast was performed radical mastectomy with axillary lymph node dissection and tumor was diagnosed as mixed invasive ductal and lobular carcinoma. Investigations for tumor staging did not show any other mass at that time. Then, she had six cures chemotherapy consisting of TAC (docetaxel-adriamycin-cyclophosphamide) and she did not receive radiotherapy. During clinical follow-ups, 18-months after chemotherapy, a rapidly progressive growing mass was recognized in her right breast. Breast ultrasound revealed a 13 cm lobulated lesion in the inner half of the breast. A spindle cell tumor with cytologic atypia was seen in intraoperative examination and then right radical

mastectomy with axillary lymph node dissection was performed relying on the possibility of metaplastic carcinoma. Grossly; tumor nodule was 12x10x8 cm sized, well circumscribed with a whorled and lobulated cutsurface and located in upper and lower inner quadrants. Histologically; tumor was composed of interlacing and parallel fascicles of spindle cells with pleomorphic nuclei and eosinophilic cytoplasm (Figure 1). Thirty-two mitoses per 10 high power fields were counted and focal necrosis was present in the tumor. All the surgical margins were free of the tumor. Histochemically, smooth muscle elements were recognised with Von Gieson and Masson Trichrom stains. Immunohistochemically; tumoral cells exhibited diffuse positivity with smooth muscle actin (Figure 2), and vimentin and desmin positivity was focally. The tumor was negative for pancytokeratin (Figure 3) and S-100. According to histological and immunohistochemical features, the tumor was diagnosed as leiomyosarcoma. Pursuant to grading system of French Federation of Cancer Centers Sarcoma Group (FNCLCC) (3) total score was 5 (score 3 for mitotic count, score 1 for necrosis and score 1 for tumor differentiation) and histological grade of tumor was considered as Grade II. Radiological examinations did not define any other tumor focus so that the possibility of metastatic tumor was ruled out. Tumor stage was accepted as Stage IIB based on the pathological and radiological findings. Although all the margins were free, radiotherapy and chemotherapy were recommended due to the tumor size and histological grade, but the patient did not accept to receive these therapies.

**İletişim/Correspondence to:** Nuray Can, Şanlıurfa Education and Research Hospital, Department of Pathology, Şanlıurfa, TURKEY

Tel: +90 414 3157849 nuraycan@ymail.com

\* This case report was presented as an abstract to 21th European Congress of Pathology (ECE) which was held in Istanbul on 8-13 September 2007.

\* Bu vaka takdimi 8-13 Eylül 2007 tarihinde İstanbul'da gerçekleştirilen 21. Avrupa Patoloji kongresinde sunulmuştur.


### Discussion

Leiomyosarcoma is not an uncommon soft tissue tumor. It can exist particularly in uterus, retroperitoneum,


**Received:** 28.03.2011 **Accepted:** 25.05.2011  
**Geliş Tarihi:** 28.03.2011 **Kabul Tarihi:** 25.05.2011

DOI: 10.5455/GMJ-30-2011-40  
www.gantep.edu.tr/~tipdergi  
ISSN 1300-0888


subcutaneous tissues and gastrointestinal tract as primary sites but it can occur throughout the body.



**Figure 1.** Tumoral spindle cells surrounding benign breast duct (H&E,  $\times 100$ ).



**Figure 2.** Smooth muscle antigen positivity in spindle cells (SMA,  $\times 200$ ).



**Figure 3.** Pancytokeratin negativity in spindle cells (Pancytokeratin,  $\times 200$ ).

Although, leiomyosarcoma of the breast can be seen as a primary or secondary (metastatic or postradiation) tumor (4), primary type is extremely rare (1). The smooth muscle component of leiomyosarcoma might be originated from the smooth muscles around the nipple or blood vessels. Also, sarcomatous change from leiomyoma or other spindle cell tumors can be the source of the tumor (5). Most of the cases are female and the median age of presentation is 56 (range 24-86) (2,6). Nearly half of the tumors are in or near the nipple-areola complex, but any quadrant can be affected (2). Clinically, they present with a progressively enlarging tumor. Radiological findings are nonspecific. In fine needle aspiration cytology, these tumors can be misdiagnosed as poorly differentiated carcinoma, metaplastic carcinoma, or other sarcomas such as malignant phylloides tumor. Immunohistochemical studies are essential for the differential diagnosis of leiomyosarcomas from other spindle cell tumors, especially metaplastic carcinoma and soft tissue sarcomas. These tumors usually exhibit positivity with desmin, smooth muscle actin, muscle specific actin and they are negative for S100 (neural tumor marker), cytokeratins and epithelial markers. The principal treatment is surgical excision with free surgical margins. Procedures of axillary node dissection are not necessary. Chemotherapy and/or radiotherapy are not suggested for smaller than 5 cm grade I tumors having free margins. If the margins are involved or closer than 2 cm, histological grade II or III and tumor is  $>8-10$  cm in size, chemotherapy and/or radiotherapy can be essential. Therefore, the tumor staging and status of surgical margins of the resection specimen defines the therapy procedures following surgery for leiomyosarcomas as in other soft tissue sarcomas (7). Long-term follow-up is important because recurrence or metastasis were reported more than 10 years after treatment (8).

Postradiation sarcomas including leiomyosarcomas of the breast following cancer therapy can occur in previously irradiated field and several years after radiotherapy. Radiation induced sarcoma diagnosis depends on the criteria established by Huvos et al (9). These tumors are associated with poor prognosis because the diagnosis is late due to the effects of prior therapy. Some authors reported that a good response to chemotherapy was observed for postradiation leiomyosarcomas and high survival rates for patients treated with chemotherapy associated surgery. So that they suggested neoadjuvant chemotherapy a potential part of treatment (10). Cyclophosphamide is an alkylating agent used commonly for the treatment of malignancies as well as for autoimmune disorders (11). Cyclophosphamide has been linked to secondary tumors such as bladder cancer, osteosarcoma, and leukemia. Therefore, it is unclear whether this type of exposure causes the development of breast leiomyosarcoma (12). De la Pena and Wapnir (13) reported a case of leiomyosarcoma of the breast with a 10-year-history of cyclophosphamide exposure. A case demonstrated two separate breast cancers and metastatic leiomyosarcoma of the thigh from retroperitoneum was reported as multiple synchronous tumors (14). The present case was

diagnosed as leiomyosarcoma after excluding the possibility of metaplastic carcinoma by demonstrating pancytokeratin negativity in several tumor sections. This tumor should be regarded as primary leiomyosarcoma of the breast, since we could not identify any other focus as a primary tumor and she had no radiotherapy. In addition, she had only received six cures of cyclophosphamide therapy for only 18 months and this time was shorter than the reported previous case in which exposure time was approximately 10 years (13). To the best of our knowledge, primary breast leiomyosarcoma with contralateral breast cancer has not been described before.

To conclude, in recent years with the increasing survival rates in breast cancer, radiation induced leiomyosarcomas seems to become more common. Postradiation leiomyosarcomas have worse prognosis and chemotherapy accompanied by surgery is suggested for these tumors rather than primary ones. Although primary leiomyosarcomas are very rare tumors, they should be kept in mind in the differential diagnosis of spindle cell breast tumors including metaplastic carcinoma in patients with prior breast cancer. Since postradiation leiomyosarcomas show worse prognosis than primary tumors, to distinguish breast leiomyosarcoma as primary or postradiation is essential.

#### References

1. Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. *Br J Cancer* 2004;91(2):237-41.
2. Rosen PP. Sarcoma. In: Weinberg RW, Donnellan K, Palumbo R, eds. *Rosen's Breast Pathology*. 3rd ed. Philadelphia, Lippincott Williams & Wilkins, 2009; 905-7.
3. Coindre JM. Grading of soft tissue sarcomas: review and update. *Arch Pathol Lab Med* 2006;130(10):1448-53.
4. Wong LC, Huang PC, Luh SP, Huang CS. Primary leiomyosarcoma of the nipple-areola complex: report of a case and review of literature. *J Zhejiang Univ Sci B* 2008;9(2):109-13.
5. Szekeley E, Madaras L, Kulka, J, Jaray B, Nagy L. Leiomyosarcoma of the female breast. *Pathol Oncol Res* 2001;7(2):151-3.
6. Gür AS, Atahan K, Tarcan E, Yiğit S, Çökmez A. An unusual breast tumor: leiomyosarcoma review of the literature. *Meme Sağlığı Dergisi* 2006;2(3):141-4.
7. Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catto CN, Wunder JS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. *J Clin Oncol* 2002;20(22):4472-7.
8. Masannat Y, Sumrien H, Sharaiha Y. Primary leiomyosarcoma of the male breast: a case report. *Case Report Med* 2010;2010:534102.
9. Huvos AG, Woodard HQ, Cahan WG, Higinbotham NL, Stewart FW, Butler A et al. Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients. *Cancer* 1985;55(6):1244-55.
10. des Guetz G, Chapelier A, Mosseri V, Dorval T, Asselain B, Pouillart P. Postirradiation sarcoma: clinicopathologic features and role of chemotherapy in the treatment strategy. *Sarcoma* 2009;2009:764379.
11. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. *Lupus* 2008;17(5):426-30.
12. Pister P, Bramwell V, Rubin B, O' Sullivan B. Sarcomas of soft tissue. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W, eds. *Clinical Oncology*. 3rd ed. Pennsylvania, Elsevier, 2004; 2574.
13. De la Pena J, Wapnir I. Leiomyosarcoma of the breast in a patient with a 10-year-history of cyclophosphamide exposure: a case report. *Cases J* 2008;1(1):301.
14. Wa CV, DeVries S, Chen YY, Waldman FM, Hwang ES. Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. *Mod Pathol* 2005;18(4):591-7.